Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: July 1, 2020
Expires: July 1, 2021
45 minutes to complete

Accredited By

Target Audience

This educational activity addresses the needs of gastroenterologists, hepatologists, and other healthcare professionals involved in the diagnosis and treatment of nonalcoholic steatohepatitis (NASH).

Learning Objectives

  • Employ current epidemiologic and demographic data to enhance NASH identification
  • Apply liver biopsy and complementary noninvasive modalities for nonalcoholic fatty liver disease (NAFLD)/NASH diagnosis, staging, and monitoring
  • Describe new insights into the pathophysiology of NAFLD/NASH progression that inform the development of emerging NASH therapies and biomarkers
  • Discuss the safety and efficacy of emerging therapies undergoing clinical development for NASH

Activity Description

NAFLD affects 24% of the American population and is projected to be the cause of nearly 800,000 excessive liver deaths from 2015 to 2030. NASH, the aggressive form of NAFLD, is a growing cause of cirrhosis and hepatocellular carcinoma and increasingly an indicator for liver transplantation. Healthcare providers would benefit from education on current epidemiologic and demographic data to enhance NASH identification, along with information on the use of liver biopsy and complementary noninvasive modalities to diagnose, stage, and monitor NAFLD/NASH progression. There is currently no FDA-approved targeted treatment for NASH. However, promising agents are undergoing late-stage clinical trials, and providers must be brought up-to-date on recent safety and efficacy outcomes. Barriers to clinical trial enrollment must also be addressed. Understanding the disease pathophysiology that informs drug development will aid in applying these agents to practice should FDA approval be obtained. This educational activity will address these knowledge gaps among healthcare providers involved in the care of patients with NASH, and application of the knowledge gained will improve patient outcomes.


Steven L. Flamm, MD
Professor of Medicine
Chief, Transplant Hepatology
Feinberg School of Medicine
Northwestern University
Chicago, Illinois

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Steven L. Flamm, MD
Consulting Fees: Intercept Pharmaceuticals
Contracted Research: Intercept Pharmaceuticals

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving CME Credit

There are no fees for participating and receiving CME credit for this activity. During the period of July 1, 2020 through July 1, 2021 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 75% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at

Statement of Commercial Support

This activity is supported by an independent educational grant from Intercept Pharmaceuticals.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.